Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly

NEW YORK, October 29, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.

--
Gilead Sciences, Inc. Research Reports
On October 16, 2014, Gilead Sciences, Inc. (Gilead) reported that Health Canada has issued a Notice of Compliance for Harvoni™ (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. The Company informed that it filed a New Drug Submission for Harvoni in Canada on March 19, 2014 and was granted Priority Review by Health Canada. The marketing authorization for Harvoni is supported by data from three Phase 3 studies, ION-1, ION-2 and ION-3. The Company stated that these studies evaluated eight, 12 or 24 weeks of treatment with Harvoni, with or without ribavirin, among nearly 2,000 genotype 1 HCV patients with compensated liver disease. The full research reports on Gilead are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/GILD/report.pdf

--
Pfizer Inc. Research Reports
On October 23, 2014, Pfizer Inc. (Pfizer) announced that the Company's Board of Directors has declared Q4 2014 dividend of $0.26 on its common stock, payable on December 2, 2014, to shareholders of record at the close of business on November 7, 2014. In addition, the Board has also authorized a new $11 billion share repurchase program to be utilized over time. The Company stated that this new program is in addition to the $1.3 billion of authorization remaining under the Company's current share repurchase program. The full research reports on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/PFE/report.pdf

--
AbbVie Inc. Research Reports
On October 20, 2014, AbbVie Inc. (AbbVie) announced that the Company's Board of Directors has increased the Company's quarterly cash dividend by 16.7% QoQ to $0.49 per share. The recently announced dividend is payable on February 13, 2015 to stockholders of record as of January 15, 2015. In addition, the Company's Board has also authorized a new $5 billion stock repurchase program, which is expected to be executed over the next several years. The Company plans to hold its Q3 2014 earnings conference call on October 31, 2014 at 8:00 a.m. CT or 9:00 a.m. ET. According to Bloomberg Businessweek's analysts, the Company is expected to report Q3 2014 EPS of $0.77 on revenue of $4.8 billion. The full research reports on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/ABBV/report.pdf

--
Edwards Lifesciences Corp. Research Reports
On October 23, 2014, Edwards Lifesciences Corp. (Edwards) released its Q3 2014 and 9M 2014 financial results. The Company's Q3 2014 net sales improved 22.6% YoY to $607.4 million, helped by 55.3% YoY growth in Transcatheter Heart Valves sales of $267.2 million. The Company's Q3 2014 net income stood at $94.6 million or $0.87 per diluted share, compared to net income of $76.8 million or $0.68 per diluted share in Q3 2013. On average, 21 analysts polled by Thomson Reuters expected the Company to report Q3 2014 EPS (excluding special items) of $0.73 per share, while Wall Street analysts' expected the Company to report revenue of $546.32 million for the quarter. The Company's 9M 2014 net sales improved 12.9% YoY to $1.7 billion, while net income improved 123.5% YoY to $701.9 million. For Q4 2014, the Company expects total sales between $575 million and $615 million, and diluted EPS (excluding special items) between $0.89 and $0.95, while for full-year 2014 the Company expects total sales between $2.05 billion and $2.25 billion, and diluted EPS (excluding special items) between $3.33 and $3.39. The full research reports on Edwards are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/EW/report.pdf

--
Eli Lilly and Co. Research Reports
On October 23, 2014, Eli Lilly and Co. (Lilly) reported 15.5% YoY decline in its total revenues to $4.88 billion, primarily due to lower volume driven by the loss of U.S. patent exclusivity for Cymbalta®, and to a lesser extent Evista®, partially offset by volume gains for most other products. The Company's Q3 2014 net income stood at $500.6 million or $0.47 per diluted share, compared to net income of $1.2 billion or $1.11 per diluted share in Q3 2013. On average, 16 analysts polled by Thomson Reuters expected the Company to report Q3 2014 EPS (excluding special items) of $0.67, while Wall Street expected revenues of $4.83 billion for the quarter. The Company's 9M 2014 total revenues declined 16.2% YoY to $14.5 billion, while net income declined 50.4% YoY to $2.0 billion. The Company also revised its full-year 2014 guidance and now expects its full-year 2014 revenue between $19.4 billion and $19.8 billion, and EPS in the range of $2.34 - $2.42. The full research reports on Lilly are available to download free of charge at:

http://www.analystsreview.com/Oct-29-2014/LLY/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED